FDA Releases Draft Guidance on Deemed License Provision of BPCI Act

Summary

The FDA is seeking public comment on a draft guidance clarifying its interpretation of a provision in the BPCI Act, which affects the labeling of biological products approved under the FD&C Act on March 23, 2020, and invites feedback on a preliminary list of approved NDAs for biological products deemed to be BLAs on the same date.